Highlights BioLineRx Ltd. Nasdaq

Equities

BLRX

US09071M2052

Market Closed - Nasdaq Other stock markets 21:00:00 31/05/2024 BST			5-day change	1st Jan Change
0.7456 ^USD	-9.05%		+23.26%	-52.51%

05-30	BioLineRx Ltd Announces Clinical Trial Agreement with St. Jude Children's Research Hospital, Inc. to Evaluate Motixafortide for CD34+ Hematopoietic Stem Cell Mobilization For Gene Therapy Applications in Sickle Cell Disease	CI
05-28	Transcript : BioLineRx Ltd., Q1 2024 Earnings Call, May 28, 2024

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

BioLineRx Ltd Announces Clinical Trial Agreement with St. Jude Children's Research Hospital, Inc. to Evaluate Motixafortide for CD34+ Hematopoietic Stem Cell Mobilization For Gene Therapy Applications in Sickle Cell Disease	05-30	CI
BioLineRx Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	05-28	CI
BioLineRx Ltd. Announces Abstract on Pilot Study Data from Phase 2 Combination Clinical Trial Evaluating Motixafortide in First-Line Pancreatic Cancer at American Society of Clinical Oncology	05-24	CI
BioLineRx Ltd. Announces Poster Presentation on Apheresis Center Efficiency and CXCR4 Antagonists Including APHEXDA® (Motixafortide) in Patients with Multiple Myeloma at the ASFA 2024 Annual Meeting	04-17	CI
BioLineRx Shares Fall After $6 Million Registered Direct Offering	04-01	MT
BioLineRx Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	03-26	CI
BioLineRx Strengthens Intellectual Property Estate with Notice of Allowance for U.S. Patent Covering Method of Manufacturing Motixafortide (Bl-8040) Suitable for Large Scale Production	03-04	CI
Biolinerx Announces First Patient Dosed in Randomized Phase 2 Combination Clinical Trial Evaluating Motixafortide in First-Line Pancreatic Cancer	02-28	CI
BioLineRx Ltd. Announces Acceptance of Two Poster Presentations on APHEXDA®? (Motixafortide) for CD34+ Hematopoietic Stem Cell Mobilization in Patients with Multiple Myeloma at the 2024 Tandem Meetings of ASTCT®?	02-16	CI
BioLineRx Announces First Patient Dosed in Phase 1 Clinical Trial Evaluating Motixafortide for CD34+ Hematopoietic Stem Cell Mobilization for Gene Therapies in Sickle Cell Disease	12-21	CI
BioLineRx Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-20	CI
BioLineRx Signs License Agreement With GloriaBio for Multiple Myeloma Drug	12/10/23	MT
Biolinerx Ltd. Announces Closing of Exclusive License Agreement to Motixafortide in Asia and Concurrent Strategic Equity Investment	12/10/23	CI
Biolinerx Ltd. Announces Encouraging Data from Pilot Phase of Phase 2 Combination Clinical Trial with Motixafortide in First-Line Pancreatic Cancer	28/09/23	CI
BioLineRx Ltd Announces FDA Approval of APHEXDA? (motixafortide) in Combination with Filgrastim (G-CSF) to Mobilize Hematopoietic Stem Cells for Collection and Subsequent Autologous Transplantation in Patients with Multiple Myeloma	11/09/23	CI
BioLineRx Ltd. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	30/08/23	CI
Biolinerx Ltd. Enters into License Agreement with Hong Seng Technology Limited and Guangzhou Gloria Biosciences Co., Ltd	30/08/23	CI
BioLineRx Ltd. Approves Appointment of Kesselman & Kesselman as Independent Registered Public Accounting Firm for the Year Ending December 31, 2023	08/08/23	CI
BioLineRx Ltd. Announces Initiation of Randomized Phase 2 Clinical Trial in First Line Metastatic Pancreatic Cancer Based on Preliminary Data from Single-Arm Pilot Phase	17/07/23	CI
BioLineRx Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023	24/05/23	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights BioLineRx Ltd. Nasdaq

Equities

BLRX

US09071M2052

Highlights

Filters